Statins are among the world’s most widely used medicines for lowering LDL cholesterol and reducing cardiovascular risk. New research from Denmark suggests that when people with type 2 diabetes begin statin treatment may also be associated with their later risk of dementia.
A 2026 Danish study found that earlier statin treatment after type 2 diabetes diagnosis was associated with a lower risk of dementia, but the observational study does not prove that statins prevent dementia.
Researchers analyzed nationwide health records from 132,585 people who developed type 2 diabetes and had not previously used statins. Starting a statin within one year of diabetes diagnosis was associated with a 15% lower relative risk of dementia over 10 years compared with not starting a statin during the first five years after diagnosis.
Starting treatment later, between one and five years after diagnosis, was associated with a smaller 10% reduction in relative risk.
The findings are intriguing, but they do not prove that statins prevent dementia. The study was observational, even though researchers used statistical methods designed to make the comparison more closely resemble a randomized trial.
Key Takeaways
- The study included 132,585 statin-naive people in Denmark who developed type 2 diabetes.
- Participants were followed for a median of 7.1 years.
- Starting statins within one year of diabetes diagnosis was associated with a 15% lower relative risk of dementia over 10 years.
- Starting statins between one and five years after diagnosis was associated with a 10% lower relative risk.
- The estimated absolute dementia risk was 3.9% without statin initiation, 3.3% with early initiation, and 3.5% with later initiation.
- The study shows an association, not proof that statins prevent dementia.
- Statins should not be started solely for dementia prevention on the basis of this study.
What Did the Researchers Study?
Ternhamar et al. (2026) used Danish national health registers to identify people who developed type 2 diabetes between 2006 and 2019.
They separated participants into three treatment strategies:
Early statin initiation: within one year of diabetes diagnosis.
Late statin initiation: between one and five years after diagnosis.
No statin initiation: no statin started within the first five years.
The researchers then compared the estimated 10-year risk of all-cause dementia.
Rather than performing a conventional observational comparison, they used a clone-censor-weight approach designed to emulate a target trial. This technique attempts to reduce some of the biases that can arise when treatment begins at different times.
It strengthens the analysis, but it does not turn an observational study into a randomized clinical trial.
How Much Lower Was Dementia Risk?
During a median follow-up of 7.1 years, 3,592 participants, or 2.7%, developed dementia.
The estimated 10-year risks were:
- 3.9% among those who did not start a statin within five years
- 3.3% among those who started within one year
- 3.5% among those who started between one and five years
Compared with no initiation, early treatment was associated with a 15% lower relative risk, while later treatment was associated with a 10% lower relative risk.
The absolute differences were considerably smaller.
Early statin initiation was associated with an estimated 0.59 percentage-point lower absolute dementia risk, while later initiation was associated with a 0.38 percentage-point reduction.
That distinction matters. Saying statins were associated with a “15% lower risk” sounds much larger than the difference between an estimated 3.9% and 3.3% 10-year risk.
Why Might Statins Be Linked to Dementia Risk?
Statins reduce LDL cholesterol and help prevent atherosclerotic cardiovascular disease.
Blood-vessel health also matters to the brain. Diabetes, elevated LDL cholesterol, hypertension, stroke, and other vascular conditions can contribute to cognitive decline and some forms of dementia.
Lowering LDL earlier could therefore theoretically reduce cumulative vascular damage over many years.
But the new study cannot establish that this is the mechanism responsible for the association.
People who begin statins earlier may also differ from nonusers in healthcare access, medication adherence, smoking, diet, exercise, blood pressure treatment, diabetes control, or other factors that are difficult to measure completely.
What Does Earlier Research Say?
The broader literature is not completely consistent.
A 2025 systematic review and meta-analysis combined 55 observational studies involving more than seven million people. Statin use was associated with a 14% lower risk of all-cause dementia and an 18% lower risk of Alzheimer’s disease. Among people with type 2 diabetes, statin use was associated with a 13% lower dementia risk (Westphal Filho et al., 2025).
However, another large 2025 study followed Kaiser Permanente members for more than a decade and found no statistically significant association between starting statins and Alzheimer’s disease or related dementias across the subgroups examined (Choi et al., 2025).
A prospective analysis of older adults also found that statin use was not associated with dementia, mild cognitive impairment, or measurable cognitive decline (Zhou et al., 2021).
That mixed evidence is one reason the Danish researchers themselves concluded that randomized trial evidence is still needed.
Does This Mean Statins Prevent Alzheimer’s Disease?
No.
The Danish study examined all-cause dementia, not simply Alzheimer’s disease.
Different forms of dementia have different biological causes. Vascular disease contributes strongly to vascular dementia and may also interact with Alzheimer’s pathology, but lowering cholesterol cannot automatically be assumed to prevent every type of dementia.
A separate 2026 U.S. real-world study found lower recorded Alzheimer’s disease incidence among statin users with dyslipidemia, but that study was also observational and its authors acknowledged that randomized trials have not established a clear dementia-prevention effect (Novak et al., 2026).
Should Someone Start a Statin to Prevent Dementia?
This study alone does not support that recommendation.
Statins are prescribed primarily to lower cholesterol and reduce the risk of cardiovascular events in people whose cardiovascular risk justifies treatment.
The Danish findings instead raise a more specific possibility: among people with type 2 diabetes who already have an indication for statin therapy, delaying treatment might also mean losing a potential long-term brain-health benefit.
That hypothesis still needs randomized evidence before dementia prevention can be considered an established reason to prescribe statins.
People already taking statins should also not stop them because of concerns about dementia without discussing the decision with their healthcare professional.
What Are the Study’s Main Limitations?
The biggest limitation is the observational design.
Even sophisticated statistical methods cannot guarantee that the early-treatment, late-treatment, and non-treatment groups were identical in all relevant ways.
The analysis also relied on diagnoses recorded in Danish national registers rather than repeated specialized neurological assessments of every participant.
The findings specifically apply to people who developed type 2 diabetes and were statin-naive at baseline. They should not automatically be generalized to people without diabetes.
The study was funded by the Danish Cardiovascular Academy and Danish Heart Foundation, rather than a statin manufacturer.
What Does This Research Actually Tell Us?
The study adds substantial evidence to the idea that cardiovascular risk management and brain health may be connected over the long term.
Among more than 132,000 people with newly diagnosed type 2 diabetes, starting a statin within one year was associated with a slightly lower estimated 10-year dementia risk than starting later or not starting during the first five years.
The association was stronger for early treatment, but the absolute difference was modest and causation remains unproven.
For now, the study should not be interpreted as evidence that statins are dementia-prevention drugs.
What it does suggest is that the timing of cholesterol treatment may deserve closer study, particularly in people with type 2 diabetes who already have elevated cardiovascular risk.
References
Ternhamar, T., Johansen, M. Ø., Nordestgaard, B. G., & Afzal, S. (2026). Association between timing of statin treatment after diabetes diagnosis and risk of dementia: A nationwide observational study. The Lancet Regional Health – Europe, 101814. https://doi.org/10.1016/j.lanepe.2026.101814.
Westphal Filho, F. L., Lopes, P. R. M., de Almeida, A. M., Sano, V. K. T., Tamashiro, F. M., Gonçalves, O. R., de Moraes, F. C. A., Kreuz, M., Kelly, F. A., & Feitoza, P. V. S. (2025). Statin use and dementia risk: A systematic review and updated meta-analysis. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 11(1), e70039. https://doi.org/10.1002/trc2.70039.
Choi, M., Zimmerman, S. C., Jiang, C., Wang, J., Swinnerton, K., Hoffmann, T. J., Oni-Orisan, A., Ferguson, E. L., Meyers, T., Choudhary, V., Whitmer, R. A., Risch, N., Krauss, R. M., Schaefer, C. M., Glymour, M. M., & Gilsanz, P. (2025). Sociodemographic modifiers of effects of statin initiation on dementia incidence: An emulated trial design in a large health care member population with 10+ years of follow-up. Alzheimer’s & Dementia, 21(3), e14627. https://doi.org/10.1002/alz.14627.
Zhou, Z., Ryan, J., Ernst, M. E., Zoungas, S., Tonkin, A. M., Woods, R. L., McNeil, J. J., Reid, C. M., Curtis, A. J., Wolfe, R., Wrigglesworth, J., Shah, R. C., Storey, E., Murray, A., Orchard, S. G., Nelson, M. R., & ASPREE Investigator Group. (2021). Effect of statin therapy on cognitive decline and incident dementia in older adults. Journal of the American College of Cardiology, 77(25), 3145–3156. https://doi.org/10.1016/j.jacc.2021.04.075
Novak, D. A., Saleem, N., Gerhardt, P. C., Maestas, D., Kejriwal, N., Vaezazizi, E., Murray, I., & Al-Khoury, L. (2026). Alzheimer’s disease in patients prescribed statins: A real-world data analysis of U.S. patient health records. Journal of Alzheimer’s Disease, 110(3), 1474–1489. https://doi.org/10.1177/13872877261424220.
